Latest Paradigm Biocapital Advisors LP Stock Portfolio
Paradigm Biocapital Advisors LP Performance:
2024 Q3: 16.71%YTD: 18.94%2023: 7.59%
Performance for 2024 Q3 is 16.71%, and YTD is 18.94%, and 2023 is 7.59%.
About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $3 Billions as of 30 Sep, 2024.
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, ACLX, . The fund has invested 17.3% of it's portfolio in NUVALENT INC and 11.3% of portfolio in ARCELLX INC .
The fund managers got completely rid off SAREPTA THERAPEUTICS INC (SRPT), CEREVEL THERAPEUTICS HLDNG I (CERE) and ASCENDIS PHARMA A/S stocks. They significantly reduced their stock positions in COMPASS PATHWAYS PLC (CMPS), DISC MEDICINE INC and OLEMA PHARMACEUTICALS INC (OLMA). Paradigm Biocapital Advisors LP opened new stock positions in VERA THERAPEUTICS INC (VERA), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and BEIGENE LTD (BGNE). The fund showed a lot of confidence in some stocks as they added substantially to APOGEE THERAPEUTICS INC, JANUX THERAPEUTICS INC (JANX) and CULLINAN THERAPEUTICS INC (CGEM).
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, ACLX, . The fund has invested 17.3% of it's portfolio in NUVALENT INC and 11.3% of portfolio in ARCELLX INC .
The fund managers got completely rid off SAREPTA THERAPEUTICS INC (SRPT), CEREVEL THERAPEUTICS HLDNG I (CERE) and ASCENDIS PHARMA A/S stocks. They significantly reduced their stock positions in COMPASS PATHWAYS PLC (CMPS), DISC MEDICINE INC and OLEMA PHARMACEUTICALS INC (OLMA). Paradigm Biocapital Advisors LP opened new stock positions in VERA THERAPEUTICS INC (VERA), MOONLAKE IMMUNOTHERAPEUTICS (MLTX) and BEIGENE LTD (BGNE). The fund showed a lot of confidence in some stocks as they added substantially to APOGEE THERAPEUTICS INC, JANUX THERAPEUTICS INC (JANX) and CULLINAN THERAPEUTICS INC (CGEM).
Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Paradigm Biocapital Advisors LP made a return of 16.71% in the last quarter. In trailing 12 months, it's portfolio return was 45.94%.
New Buys
| Ticker | $ Bought |
|---|---|
| vera therapeutics inc | 48,480,800 |
| moonlake immunotherapeutics | 46,965,200 |
| beigene ltd | 44,977,400 |
| spyre therapeutics inc | 37,279,600 |
| pliant therapeutics inc | 34,801,300 |
| keros therapeutics inc | 30,488,900 |
| oruka therapeutics inc | 17,638,900 |
New stocks bought by Paradigm Biocapital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| apogee therapeutics inc | 112 |
| janux therapeutics inc | 53.45 |
| cullinan therapeutics inc | 50.44 |
| erasca inc | 47.15 |
| cogent biosciences inc | 27.19 |
| merus n v | 21.54 |
| edgewise therapeutics inc | 19.94 |
| immatics n.v | 14.11 |
Additions to existing portfolio by Paradigm Biocapital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| compass pathways plc | -50.34 |
| disc medicine inc | -44.63 |
| olema pharmaceuticals inc | -30.37 |
| argenx se | -10.73 |
| kura oncology inc | -4.58 |
| arvinas inc | -4.03 |
| viridian therapeutics inc | -0.02 |
Paradigm Biocapital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| vor biopharma inc | -6,457,290 |
| cerevel therapeutics hldng i | -95,294,500 |
| xenon pharmaceuticals inc | -79,667,500 |
| alx oncology hldgs inc | -9,500,900 |
| legend biotech corp | -53,294,500 |
| bridgebio pharma inc | -27,596,800 |
| sarepta therapeutics inc | -149,717,000 |
| verona pharma plc | -10,426,900 |
Paradigm Biocapital Advisors LP got rid off the above stocks
Sector Distribution
Paradigm Biocapital Advisors LP has about 84.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 84.3 |
| Others | 15.7 |
Market Cap. Distribution
Paradigm Biocapital Advisors LP has about 1.6% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 57.8 |
| SMALL-CAP | 24.8 |
| UNALLOCATED | 15.7 |
| MEGA-CAP | 1.6 |
Stocks belong to which Index?
About 75.2% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 75.2 |
| Others | 24.8 |
Paradigm Biocapital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP has 31 stocks in it's portfolio. About 65.9% of the portfolio is in top 10 stocks. MRUS proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 11.30 | 4,000,000 | 334,040,000 | added | 3.95 | ||
| AGLE | spyre therapeutics inc | 1.26 | 1,267,580 | 37,279,600 | new | |||
| ALXO | alx oncology hldgs inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 1.95 | 2,339,960 | 57,633,200 | reduced | -4.03 | ||
| BBIO | bridgebio pharma inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BGNE | beigene ltd | 1.52 | 200,336 | 44,977,400 | new | |||
| CERE | cerevel therapeutics hldng i | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics inc | 1.31 | 2,321,010 | 38,853,800 | added | 50.44 | ||
| CMPS | compass pathways plc | 0.25 | 1,160,000 | 7,308,000 | reduced | -50.34 | ||
| COGT | cogent biosciences inc | 1.68 | 4,609,760 | 49,785,400 | added | 27.19 | ||
| CRNX | crinetics pharmaceuticals in | 4.35 | 2,516,690 | 128,603,000 | added | 0.13 | ||
| ERAS | erasca inc | 0.98 | 10,668,100 | 29,124,000 | added | 47.15 | ||
| EWTX | edgewise therapeutics inc | 2.52 | 2,789,170 | 74,443,000 | added | 19.94 | ||
| IMVT | immunovant inc | 1.31 | 1,362,830 | 38,854,200 | unchanged | 0.00 | ||
| JANX | janux therapeutics inc | 3.69 | 2,400,570 | 109,058,000 | added | 53.45 | ||
| KROS | keros therapeutics inc | 1.03 | 525,037 | 30,488,900 | new | |||
| KURA | kura oncology inc | 2.86 | 4,331,320 | 84,634,000 | reduced | -4.58 | ||
| MLTX | moonlake immunotherapeutics | 1.59 | 931,480 | 46,965,200 | new | |||
| MRUS | merus n v | 4.15 | 2,454,920 | 122,648,000 | added | 21.54 | ||
| NUVL | nuvalent inc | 17.30 | 5,000,000 | 511,500,000 | added | 9.37 | ||